PART I Overview We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies. Our strategy is to identify immune-mediated diseases in which translational and c...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001104659-26-032080 | EDGAR | 96K words |
| 2025-03-25 | 2024-12-31 | 0001410578-25-000443 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001410578-24-000329 | EDGAR | — |
| 2023-03-28 | 2022-12-31 | 0001410578-23-000374 | EDGAR | — |
| 2022-04-11 | 2021-12-31 | 0001410578-22-000860 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001104659-25-110793 | EDGAR | 36K words |
| 2025-08-14 | 2025-06-30 | 0001410578-25-001783 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001410578-25-001100 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001410578-24-001779 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001410578-24-001371 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001410578-24-000655 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001410578-23-002337 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001410578-23-001829 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001410578-23-001121 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001410578-22-003377 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001410578-22-002385 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001410578-22-001433 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001104659-26-032077 | EDGAR | 6K words |
| 2026-03-10 | 0001104659-26-025520 | EDGAR | — |
| 2026-03-05 | 0001104659-26-023806 | EDGAR | — |
| 2026-02-26 | 0001104659-26-019827 | EDGAR | — |
| 2026-02-23 | 0001104659-26-018312 | EDGAR | — |
| 2026-02-11 | 0001104659-26-012935 | EDGAR | — |
| 2026-01-26 | 0001104659-26-006326 | EDGAR | — |
| 2026-01-12 | 0001104659-26-002688 | EDGAR | — |
| 2026-01-02 | 0001104659-26-000209 | EDGAR | — |
| 2025-12-17 | 0001104659-25-121826 | EDGAR | — |
134 total filings indexed. 107 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001855644 |
| Ticker | ZURA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | E9 |
| Website | https://www.zurabio.com |
| Listed | 2023-03-21 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report